Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
NEW YORK, Nov 14 (Reuters) -Bristol Myers Squibb BMY.N was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.
The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by dragging its heels in seeking approval of the drugs, including the cancer drug Breyanzi, by specified deadlines. It said Bristol Myers did this to avoid a big payout.
On Sept. 30, U.S. District Judge Jesse Furman in Manhattan ruled that the plaintiff UMB Bank had never been properly appointed trustee to represent the CVR holders.
He said this "inexplicable failure" doomed the earlier lawsuit that UMB filed after purportedly replacing a different trustee, and 17 months after Bristol Myers bought Celgene for $80.3 billion.
In Thursday's complaint, UMB said it has addressed the judge's concerns and been confirmed as trustee, entitling it to sue. Bristol Myers' estimated $6.7 billion liability is up from $6.4 billion mentioned in earlier court papers.
Neither Bristol Myers nor its lawyers immediately responded to requests for comment after market hours. UMB's lawyers did not immediately respond to separate requests.
Bristol Myers won U.S. Food and Drug Administration approval for Breyanzi to treat non-Hodgkin's lymphoma on Feb. 5, 2021, five weeks after the relevant deadline for the CVR holders.
The case is UMB Bank NA v Bristol-Myers Squibb Co, U.S. District Court, Southern District of New York, No. 24-08668.
Reporting by Jonathan Stempel in New York; Editing by Stephen Coates
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
